EMA recommends approval of new therapy against HIV

The Committee For Medicinal Products for Human Use has recommended to grant a marketing authorization for the medicinal product Tivicay.

Tivicay that seems to be effective in struggle with the resistant HIV. Dolutegravir - its active substance is a new substance inhibiting the integrase enzyme. A less frequent, but potentially serious allergic reaction can be one of its adverse effects.

The original article can be found here.


Register for receiving PharmaAround news, register for PharmAround events.
Continue registration